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the prognosis for the majority of patients has not changed signif-
icantly over the past few decades. For patients with advanced dis-
ease, sorafenib is currently the standard of care providing a
survival advantage of 2–3 months in selected patients. Cytotoxic
chemotherapy has been used for over 30 years but deﬁnite evi-
dence that it prolongs survival has been lacking. Resistance
remains a signiﬁcant barrier for both targeted and cytotoxic
agents and an understanding of the underlying mechanisms is
critical if outcomes are to be improved. Here, we summarise
the past and current data that constitute the evidence base for
chemotherapy in HCC, review the causes of chemoresistance
and suggest strategies to overcome these barriers.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatocellular cancer (HCC) is the third most common cause of
cancer death worldwide with incidence matching mortality
reﬂecting the poor prognosis of this disease. Potentially curative
interventions such as transplantation, resection, and thermal
ablation are applicable for the 30% whose tumours or liver func-
tion meet deﬁned criteria [1]. Even among those treated with
curative intent, relapse rates are up to 50%. For patients who have
large or multifocal disease but with good liver function, perfor-
mance status, and a patent main portal vein, trans-arterial
chemoembolization has been shown to improve survival com-
pared to best supportive care [2]. Of the remaining 50% patients,
around 10–20% will have such advanced tumours or liver disease
that only supportive care is appropriate leaving 20–30% poten-
tially suitable for palliative systemic therapy [3]. For those that
are potential candidates for systemic therapy, the expected med-
ian survival without treatment ranges from 4 to 8 months based
on outcomes from best supportive care (BSC) or placebo arms ofJournal of Hepatology 20
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E-mail address: t.meyer@ucl.ac.uk (T. Meyer).was no proven effective systemic therapy. However, the demon-
stration that the multi-targeted kinase inhibitor sorafenib results
in a 44–47% improvement in median overall survival has dis-
missed the prevailing nihilism that HCC is an unresponsive
tumour and has established a new standard of care [5,7]. Sorafe-
nib is the standard against which future systemic therapies need
to be measured and is currently the control arm for several ongo-
ing randomised phase III trials.
Chemotherapy has been widely regarded as ineffective
because of toxicity and poor response, however, recent trials,
with appropriate patient selection, have provided some evidence
that chemotherapy may have a role. Furthermore, a greater
understanding of the molecular mechanisms of tumour resis-
tance, and how to overcome them, present an opportunity to
explore the combination of chemotherapy with targeted agents,
or to select patient groups that are more likely to respond. Here,
we summarise the past and current data that constitute the evi-
dence base for chemotherapy in HCC, review the causes of
chemoresistance and suggest strategies to improve outcomes.Systemic chemotherapy – historical perspective
Systemic chemotherapy has been used for the treatment of
advanced HCC for over 30 years but deﬁnitive evidence that cyto-
toxic drugs improve survival compared to BSC has not been pro-
vided [8]. The report by Olweny [9] in 1975 of a 79% response rate
for doxorubicin in a small single arm phase II trial was followed
by a series of further uncontrolled phase II trials and resulted in
doxorubicin being regarded by many as the standard chemother-
apy drug for this disease. The reported response rates in the sub-
sequent studies did not conﬁrm the original study and have
varied between 1% and 35%. Meanwhile a range of other drugs
and combinations have also been assessed [8,10]. The PIAF regi-
men (cisplatin, interferon, doxorubicin and ﬂuorouracil) was ini-
tially reported to have a response rate of 26% in a phase II trial of
ﬁfty patients, however, it was associated with signiﬁcant toxicity
including 2 treatment related deaths [11]. Importantly, this trial
did conﬁrm the chemosensitivity of HCC demonstrating a com-
plete pathological response in four out of nine patients who went
on to surgical resection.
Remarkably, there are only two small randomised trials that
have compared chemotherapy with BSC. One study of
106 patients compared doxorubicin with BSC reporting a median12 vol. 56 j 686–695
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survival of 2.7 vs. 1.9 months respectively and a 25% mortality
rate associated with doxorubicin [12]. Although this trial was sta-
tistically signiﬁcant, the survival in both groups was well below
that expected and cannot be regarded as deﬁnitive evidence of
efﬁcacy. Moreover, the treatment related mortality was in excess
of that seen in subsequent doxorubicin trials where treatment
related mortality was 3% or less [13]. A second study compared
enteric coated tegafur/uracil to best supportive care in a random-
ised trial of 56 patients with HCC [14]. Overall survival in the
treated group was 12.1 months while that in the BSC group was
only 6.2 months. However, almost a third of the BSC group were
not included in the ﬁnal analysis leading to potential bias in an
already small and underpowered study. Consequently, previous
systematic reviews have concluded that chemotherapy has no
role in the treatment of HCC [2,10].Randomised trials
In the past few years, there have been four large randomised tri-
als reported, two of which provide some evidence that chemo-
therapy may improve survival. All have used doxorubicin rather
than BSC as the control arm (Table 1). In a trial performed in
Hong Kong, doxorubicin was compared with PIAF (n = 188) and,
while the superior response rate of PIAF was conﬁrmed; 10.5%
vs. 20.9%, the difference in survival; 6.8 vs. 8.7 months, was not
signiﬁcant [13]. The b-tubulin binding drug T138067 which
inhibits microtubule formation was studied in a large global trial
(n = 339) and found to have an almost identical median survival
to doxorubicin (5.7 vs. 5.6 months respectively) [15]. This trial
remains in abstract form only despite having been presented in
2005. The thymidylate synthase inhibitor nolatrexed was com-
pared to doxorubicin (n = 445) in a trial conducted in Western
patients and found to a have signiﬁcantly worse survival than
doxorubicin; 5.1 vs. 7.4 months respectively (HR 0.753
p = 0.0068) [16]. Nolatrexed was also associated with more toxic-
ity with a greater number of patients withdrawn due to adverse
events, patient choice or death. Finally, the combination of oxa-
liplatin and ﬂuorouracil (FOLFOX 4) has been compared with
doxorubicin in a large population of Asian patients (n = 371)
[17]. Although presented and published in abstract form in
2010, the full publication is not available. The median survival
in the doxorubicin arm was 5.0 months and 6.4 months for FOL-
FOX 4. At the ﬁnal analysis after 249 events, the result failed to
achieve signiﬁcance (HR 0.797 [0.625, 1.017] p = 0.0695). How-
ever, on longer follow-up after 305 events, the difference just
achieved signiﬁcance (p = 0.0425). It is notable that this trial used
doxorubicin at a lower dose of 50 mg/m2 in contrast to the three
preceding trials that all used 60 mg/m2.Table 1. Randomised controlled trials of doxorubicin for HCC.





Yeo et al., [13] 188 Dox1 10.5 6.8 PIA
Posey et al., [15] 339 Dox1 4.0 5.6 T13
Gish et al., [16] 445 Dox1 4.0 7.4 Nol
Qin et al., [17] 371 Dox2 2.7 5.0 FOL
1Dox at 60 mg/m2.
2Dox at 50 mg/m2.
RR, partial response rate according to WHO or RECIST.
Journal of Hepatology 201What can be concluded from these trials is that real response
rate to doxorubicin is between 2% and 10% and that both doxoru-
bicin and the FOLFOX 4 regimen may provide some survival ben-
eﬁt in comparison to control treatment.How does chemotherapy compare with sorafenib?
Sorafenib is an oral multi-targeted kinase inhibitor which blocks
tumour growth and angiogenesis by inhibition of Raf, RET, FLT3
c-Kit, VEGFR-1,-2 and -3, and PDGF-a and -b. Two placebo con-
trolled randomised phase III trials have now been reported, both
of which have conﬁrmed a signiﬁcant survival advantage in
favour of sorafenib. The ﬁrst, performed in a predominantly
Western population demonstrated a response rate of only 2%
but a 44% improvement in median overall survival from 7.9 to
10.7 months (HR 0.69, p <0.001) [5]. The second trial, conducted
in an Asian population, again demonstrated a low response rate
at 3.3% but conﬁrmed a 47% improvement in overall survival
from 4.2 to 6.5 months (HR 068, p = 0014] [7]. The lower abso-
lute difference in survival between the two trials was attributed
to more advanced disease in the Asian patients as indicated by
number of disease sites and worse performance status.
With the establishment of sorafenib as the standard of care, it
is no longer possible to conduct a trial comparing chemotherapy
with BSC and to our knowledge there are no trials underway to
directly compare sorafenib with chemotherapy. The best that
can be done is to compare efﬁcacy and toxicity across trials in
similar patient populations as deﬁned by key prognostic criteria.
Performance status, Child–Pugh score, and tumour burden have
been proposed as stratiﬁcation factors in trials of BCLC stage C
[18] patients [3] and a recent analysis of predictors of one-year
survival in patients with BCLC stage B and C disease identiﬁed
six factors associated with increased survival: publication before
2000, low prevalence of alcoholic liver disease, high prevalence of
HCV-related disease, high percentage of ECOG PS = 0, low per-
centage of patients with ascites, and high percentage of Okuda
stage I disease [19]. In comparing across trials, these factors need
to be considered and are summarised in Table 2.
An important aspect of both sorafenib trials was the selection
of only Child–Pugh A patients so that the impact of coexistent
liver disease on the survival endpoint was minimised. The only
randomised trial in the Western population using chemotherapy
was that performed by Gish et al. [16] in which only 73% were
Child–Pugh A compared to 95% in the SHARP trial [5]. Thus, we
do not have a matched Western patient group treated with
chemotherapy or sorafenib and are unable to make a meaningful
comparison. However, for the Asia-Paciﬁc populations, the key







F 20.9 8.7 0.97 0.83 
8067 2 5.7 n.a. 0.85 
atrexed 1.4 5.1 0.753 0.0068 
FOX 4 8.2 6.4 0.797 0.070
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Table 2. Comparison of patient characteristics and outcome for patients treated with chemotherapy and sorafenib in randomised trials.
Western population
Author, [Ref.] Llovet et al., [5] Gish et al., [16] Cheng et al., [7] Yeo et al., [13| Qin et al., [17]
Therapy Sorafenib Doxorubicin Sorafenib Doxorubicin FOLFOX 4
No. patients 299 222 150 94 184
Age (yr) 65 n.a. 51 54 50
% Child Pugh A 95 73 97 82 89
% with PS 0 54 62 25 87 -
% with PS 0/1 92 86 92 92 -
% with Hep C 29 43 10 8 5
% with ALD 26 26 - - -
% with Mets 53 52 69 n.a. 56
% BCLC  C 82 n.a. 95 n.a. 79
Median OS (mo) 10.7 7.4 6.5 6.8 6.4
Asia pacific population
Reviewaetiology, Child–Pugh score and performance status. Survival
across the three trials is more or less identical (Table 2). Toxicity
is also an important consideration in comparing treatment
modalities. For sorafenib treated patients the dominant side
effects are diarrhoea and hand foot skin reaction (HFSR), occur-
ring at grade 3 or 4 in 8–11% but no treatment related deaths
were reported in either the SHARP trial or the Asia-Paciﬁc study
[5,7]. For the Western population of patients treated with doxo-
rubicin, the dominant symptomatic grade 3 and 4 toxicity was
fatigue occurring in 10.8% of patients with no treated related
deaths reported [16], while in the Asian population febrile neu-
tropenia occurred in 17% and there was a 3% treatment related
mortality [13]. Full toxicity data relating to FOLFOX for HCC
remains to be published [17].Combining chemotherapy with sorafenib and other targeted
agents
In common with other cancers, a number of key signalling path-
ways are dysregulated in HCC providing an opportunity for phar-
macological intervention with targeted agents [20] (Fig. 1).
Combining targeted therapy with chemotherapy improved sur-
vival in several tumour types and similar combinations have been
explored in HCC (Table 3). The combination of doxorubicin and
sorafenib has been explored in a phase I dose escalation trial
which demonstrated that both drugs could be given at full dose
without additional toxicity despite the slight increase in doxoru-
bicin exposure [21]. Eighteen patients with advanced HCC were
enrolled in a follow-on study conﬁrming a modest increase in
the AUC (21%) and Cmax (33%) for doxorubicin. The most frequent
non-haematological toxicity was diarrhoea and dose reductions
or discontinuation of sorafenib was required in 33% cases due
to emergent toxicity, most commonly HFSR [22]. Recently the
results of a randomised double blind placebo controlled phase
II (n = 96) trial comparing the combination of doxorubicin and
sorafenib vs. doxorubicin alone have been published [23]. The
primary endpoint was time to progression which was superior
in the combination group; median 6.4 vs. 2.8 months (p = 0.02),
and overall survival, a secondary endpoint, was improved from
a median of 6.5 to 13.7 months (p = 0.006). Adverse events were688 Journal of Hepatology 201consistent with the known toxicity proﬁle of sorafenib with HFSR
in 6.4% and diarrhoea in 10.6% of those receiving the combina-
tion. Haematological toxicity was not increased by the addition
of sorafenib but all grade systolic dysfunction and hypertension
was more common with the combination; 19% vs. 2% and 17%
vs. 0% respectively. While the difference in survival appears
impressive, this trial cannot determine what, if any, additional
contribution was made by doxorubicin in the combination arm.
With sorafenib now established as the standard of care, a trial
comparing sorafenib vs. sorafenib combined with doxorubicin is
required and is currently underway.
Bevacizumab, the anti-VEGF monoclonal antibody, has proved
effective in combination with chemotherapy for breast [24] and
colon cancer [25–27] despite its limited single agent activity. In
HCC there have only been single arm phase II trials exploring a
number of different chemotherapy regimens with bevacizumab
[28–30] (Table 3). Results are in line with those of chemotherapy
or bevacizumab alone [31–33] but no randomised trials are avail-
able. The anti-EGFR antibodies cetuximab and panitumumab,
have also been effectively combined with chemotherapy in colo-
rectal cancer [34,35] where response has been linked to KRAS
mutational status. In HCC there is only one reported phase II trial
in which anti-EGFR therapy, using cetuximab, has been combined
with chemotherapy [36] (Table 3) and further studies are needed.Overcoming chemoresistance in HCC
In general, a variety of mechanisms contribute to chemoresis-
tance including tumour hypoxia, expression of DNA repair
enzymes and abrogation of apoptotic effector pathways by
altered expression of genes such as TP53. For doxorubicin, one
of the most important causes of resistance is increased expres-
sion of the drug transporter family known as the ATP-binding
cassette (ABC) transporters. The most common member of this
family is the ABCB1 (also known as MDR1; multidrug resistance
gene 1) which encodes for P-glycoprotein. Overexpression of
P-glycoprotein is associated with lower accumulation of doxoru-
bicin in HCC cells and with worse prognosis in patients. Recent
progresses in our understanding of mechanisms of resistance in
HCC present opportunities to improve the response to cytotoxic2 vol. 56 j 686–695
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Fig. 1. Activated signal transduction pathways in HCC and associated molecularly targeted agents. PDGFR, platelet derived growth factor receptor; EGFR, epidermal
growth factor receptor; FGFR, ﬁbroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor.
JOURNAL OF HEPATOLOGYagents. Potential strategies are discussed below and summarised
in Table 4.
Targeting G2 in TP53 mutated tumours
An important mechanism of action for many anti-cancer agents,
including platinum based drugs, is the induction of DNA damage.
This causes the stabilisation of p53 leading to cell cycle arrest and
DNA repair or apoptosis depending on the extent of the damage.
TP53 mutations occur in around 50% of human carcinomas and
are an important cause of drug resistance. In HCC, the worldwideTable 3. Trials in which chemotherapy has been combined with targeted agents.
Author, [Ref.] Targeted agent Chemotherapy No. patie
Abou-Alfa et al., [26] Sorafenib Doxorubicin 47
Hsu et al., [65] Sorafenib Tegafur/uracil
(Metronomic)
53
Asnacios et al., [39] Cetuximab Gemcitabine 
Oxaliplatin
45
Zhu et al., [31] Bevacizumab Gemcitabine 
Oxaliplatin
33
Sun et al., [32] Bevacizumab Capecitabine
Oxaliplatin
45
Hsu et al., [33] Bevacizumab Capecitabine 45
PFS, Progression free survival; OS, Overall survival.
Journal of Hepatology 201prevalence of TP53 mutations has been estimated at around 28%
[37] and 37% in the Chinese population [38]. The highest rates are
seen in aﬂatoxin exposed populations in which over 50% have a
speciﬁc mutation at codon 249 [39]. In addition, the X gene of
HBV (HBx), which integrates into the host genome, is frequently
mutated, yet mutant HBx proteins retain their ability to bind
to p53 and attenuate p53-mediated DNA repair and apoptosis
[40].
p53 is required for regulation of the G1 checkpoint, but even
in the absence of functional p53, cancers retain the G2 checkpoint
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Table 4. Overview of the mechanisms of resistance to chemotherapy in hepatocellular carcinoma (HCC).





Resistance to drug induced apoptosis by loss of G1 checkpoint regulation
Block G2 cell cycle check point
• AZD7762 inhibits the protein kinase 
Chk1 




Activation of the PI3K/AKT/mTOR pathway 
Dysregulated growth and evasion of apoptosis
Inhibit mTOR in p53 wild-type tumors 




Expression of HIF-1 leading to increased VEGF and PDGF which promote 
angiogenesis and drug resistance 
Block VEGF and PDGF
• sorafenib (Fig. 3)
Cause
Effect
Expression of DNA repair enzymes e.g. ERCC1 





Increased expression of AEG-1 
Increase expression of MDR1 gene and resistance to doxorubicin 
Block the expression of AEG-1
Block expression of  MDR1
Reviewdamage. Targeting the G2 checkpoint in TP53 mutated tumours
therefore allows cells carrying DNA lesions into mitosis, prompt-
ing mitotic catastrophe and cell death. Potentially, this strategy
provides a means of selectively sensitising tumour cells to
chemotherapy-induced DNA damage since normal tissues retain
intact functional p53 (Fig 2). Thus, the combination of Chk1 inhi-
bition and DNA damage could provide a means of targeting cells
in which G1 is already defective. AZD7762 is a potent ATP-com-
petitive checkpoint kinase inhibitor that has been evaluated in
preclinical models in combination with the antimetabolite gem-
citabine, and the topoisomerase-1 inhibitor irinotecan. Both
drugs induce G2 arrest, which is abrogated by the addition of
AZD7762 and in xenografts, the combination of cytotoxics was
more effective than either drug used separately [41]. Phase 1 tri-
als of AZD7762 in combination with gemcitabine have been com-
pleted but not yet reported. Another key regulator of the G2
checkpoint is cycline dependent kinase-1 (CDC2), which is inacti-
vated by phosphorylation mediated by the tyrosine kinase, Wee-
1 (Fig. 2). Inhibition of Wee-1 by the small molecule MK-1775 has
recently been shown to abrogate the G2 DNA damage checkpoint
and induce apoptosis in response to the cytotoxic drugs gemcit-
abine, carboplatin and cisplatin, but is inactive as a single agent
[42]. The effect was selective for p53-deﬁcient cell lines and
caused little toxicity in vivo. Of interest, the phosphorylation of
CDC2Y15 can be measured in skin hair follicles providing a clin-
ically applicable pharmacodynamic biomarker. Phase I dose esca-
lation trials are currently underway on MK-1775 as both a single
agent or in combination with gemcitabine, cisplatin and carbo-
platin in solid cancers.
Targeting the PI3K/Akt/mTOR pathway
The phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target
of rapamycin (mTOR) pathway is an important growth factor sig-
nalling pathway that mediates several cellular processes includ-
ing proliferation, survival and motility. Increased activation of
this pathway is common in cancer, driving tumorigenesis and
conferring resistance to chemotherapy. For example Wang et al.
have shown that the oncogenic transcription factor octamer 4
(Oct4) is upregulated in chemotherapy resistant HCC cell lines
due to demethylation of the Oct4 gene [43]. Overexpression is
associated with increased expression of stem cell markers includ-
ing CD133, CD90 and CD19, tumourigenicity and the activation of690 Journal of Hepatology 201Akt. In addition, there was upregulation of the drug efﬂux pump
ABCG2 which could be inhibited by the PI3K inhibitor LY294002,
suggesting the presence of an Oct4-AKT-ABCG2 pathway in resis-
tant HCC. Further evidence that Akt is important for chemoresis-
tance in HCC stem cells comes from cell sorting experiments in
which the CD133+ subgroup (stem cell phenotype) was found
to have greater resistance to doxorubicin, and 5FU compared
with CD133 cells [44]. The mechanism of resistance was
reduced apoptosis associated with activation of Akt and Bcl2 sur-
vival pathways with inactivation of proapoptotic BAD. In this
model, the preferential survival of CD133+ cells in the presence
of chemotherapy could also be abolished by inhibition of Akt.
CD133+ are known to account for 1.3–13.6% of cells in the bulk
of primary HCC cells yet may be the critical target since they have
property of self replication.
There are number of inhibitors of mTOR available in the clinic,
including sirolimus, everolimus, temsirolimus and AP23573. As
single agents, these drugs are cytostatic and have little effect
on apoptosis yet, in combination with cytoxic drugs such as cis-
platin, have been shown to enhance apoptosis [45,46]. The effect
is p53-dependent and not observed in TP53 / or TP53 mutant
cell lines and appears to be mediated by an effect on p21 (Fig
3). Thus, there is a clear rationale for combining DNA damaging
agents with mTOR inhibitors in p53 wild type tumours.
Even in TP53 wild type tumours, the approach may be valid
since in vivo studies suggest combination therapy is effective
through inhibition of angiogenesis. Piguet et al. have shown that
combination of doxorubicin and sirolimus is more effective than
either drug alone in a TP53 mutant HCC rat model [47]. The
reduced growth was associated with reduced angiogenesis and
lowered levels of p21 in the endothelial cells which were TP53
wild type.
Another approach to increasing chemosensitivity by modula-
tion of the mTOR pathway is to mimic endogenous regulators.
MicroRNAs (miRNAs) are small RNA sequences that bind to target
RNA sequences thereby regulating post-transcriptional expres-
sion. MicroRNA-199a-3p (miR-199a-3p) has been shown to bind
directly to mTOR mRNA and decrease mTOR protein expression
with a consequent restoration of sensitivity to doxorubicin in
HCC cell lines presenting an opportunity to develop analogues
that can mimic this activity [48].
Clinical trials combining mTOR inhibitors with both chemo-



























DNA damaging cytotoxic chemotherapy  
Fig. 2. Pharmacological mechanisms to abrogate the G2 cell cycle checkpoint
by inhibition of Wee-1 kinase and Chk 1. (A) Cell cycle: p53 is the key regulator
of G1 checkpoint while p53 deﬁcient tumours are dependent on G2 checkpoint.
(B) The G2 checkpoint is regulated by the protein kinase Chk1, which is activated
in response to DNA damage. Chk1 phosphorylates the protein phosphatase Cdc25,
preventing Cdc25 from dephosphorylating and activating Cdc2. Inhibition of
Chk1, therefore, promotes entry into mitosis. Similarly inhibition of Wee-1 also
prevents mitotic delay by inhibiting phosphorylation of Cdc2. Green arrow








Fig. 3. DNA damage induced by cisplatin activates p53 which increases levels
of p21 leading to cell cycle arrest allowing potential for DNA repair. In the
presence of the mTOR inhibitor everolimus, the rise in p21 is inhibited favouring
an apoptotic response to p53 activation mediated by the pro-apoptotic molecules
Puma, Noxa and Bax.
JOURNAL OF HEPATOLOGYOvercoming hypoxia associated chemoresistance
Hypoxia has been proposed a signiﬁcant cause of chemoresis-
tance and is particularly relevant in the treatment of HCC in
which chemotherapy is administered with the concurrent induc-
tion of acute hypoxia during transarterial chemoembolisation
(TACE). The cellular response to hypoxia is mediated by
hypoxia-inducible (HIF-1), a heterodimer composed of HIF-1a
and HIF-1b. Under normoxic conditions HIF-1a is rapidly hydrox-
ylated, ubiquinated and degraded by the proteosome. In hypoxic
conditions, hydroxylation is inhibited allowing HIF-1a levels to
rise and dimerise with HIF-1b. The dimer binds to the hypoxia
response elements, transactivating a number of genes responsi-
ble for angiogenesis, erythropoiesis and glycolysis. RecentJournal of Hepatology 201evidence also suggests that PDGF is a target gene for HIF-1 and
that an autocrine loop involving Akt/HIF and PDGF is responsible
for hypoxia-induced resistance to cisplatin (Fig. 4) [49]. Hence,
the combination of chemotherapy with inhibitors of PDGF signal-
ling or the AKT pathway provides a potential means of overcom-
ing hypoxia-induced resistance and there is a clear rationale for
combining sorafenib, which blocks PDGF signalling, with TACE
or systemic chemotherapy.
Targeting angiogenesis with chemotherapy – metronomic
chemotherapy
The fact that proliferating endothelial cells are genetically stable
and less prone to develop drug resistance is one of the key justi-
ﬁcations for targeting angiogenesis for cancer therapy. The con-
cept of chemotherapy as an anti-angiogenic therapy was ﬁrst
proposed by Browder et al. [50] as a means of overcoming tumour
chemoresistance. Conventional chemotherapy is given at high
doses according to intermittent schedules that allow normal tis-
sue, including proliferating endothelium and bone marrow cells,
to recover. By administering continuous, low dose cyclophospha-
mide, drug resistant tumours were more effectively treated as
compared with conventional doses and schedules. Endothelial
cell apoptosis was shown to precede tumour cell apoptosis sug-
gesting the tumour growth was inhibited by the antiangiogenic
effect of cyclophosphamide [50]. Combining so called ‘metro-
nomic chemotherapy’ with other antiangiogenic approaches,
such as inhibition of VEGFR-2, has proved even more effective
in preclinical experiments [51–53]. Clinical trials of metronomic2 vol. 56 j 686–695 691
Fig. 4. Hypoxia causes an increase in the transcription factor hypoxia
inducible factor HIF-1a which transactivates a number of hypoxia responsive
genes including platelet derived growth factor (PDGFb) and vascular endo-
thelial growth factor (VEGF). In an autocrine feedback loop, PDGF binds to its
receptor activating the phosphatidylinositol 3-kinase (PI3K)/Akt pathway which
in turn increases HIF-1a. The activation of Akt promotes drug resistance via
activation of glycogen synthase kinase-3b (GSK-3b). The feedback loop can be
inhibited by the PI3K inhibitor LY294002, the HIF-1a inhibitor YC1 or the PDGF
receptor inhibitor AG1296 [49].
Reviewchemotherapy [54] have been reported in a number of different
tumour types including breast [55,56], ovarian [57], glioblastoma
[58] and non-Hodgkin’s lymphoma [59].
Recently, there has been growing interest in exploring the
potential beneﬁts of metronomic chemotherapy in advanced
HCC given its relative chemoresistance.
In a orthotopic model of HCC, metronomic chemotherapy
with cyclophosphamide, tagefur-uracil (UFT), doxorubicin or a
combination thereof was found to be ineffective but, with the
addition of VEGR-2 inhibition with the antibody DC101, was
more effective than chemotherapy or DC101 alone [60]. Further-
more, in a model of acquired resistance to sorafenib, the combi-
nation of UFT and low dose sorafenib delayed the emergence of
resistance and reduced toxicity compared to a higher dose of
sorafenib alone [61].
The combination of sorafenib and metronomic UFT has been
taken forward in a phase II trial of 53 patients from Taiwan
[62]. Patients were unsuitable for locoregional therapy, had
Child–Pugh A liver disease and ECOG performance scores 0–2.
The majority were hepatitis B surface antigen positive and had
extrahepatic disease. Patients received sorafenib 400 mg BD and
UFT continuously as ﬁrst line therapy for advanced HCC and con-
tinued until disease progression or unacceptable toxicity. At a
median follow up of 16.1 months, the median PFS was
3.7 months (95% CI: 1.9–5.5) and median OS 7.4 months (95% CI692 Journal of Hepatology 2013.4–11.4). According to the RECIST criteria, ORR was 8% (CR = 0;
PR = 4) with 26 patients achieving disease stabilisation. The
authors concluded that metronomic UFT can be safely combined
with sorafenib and appears to improve efﬁcacy of sorafenib in
advanced HCC with minimal haematological toxicities. Predomi-
nant side effects were similar to sorafenib monotherapy with
HFSR, diarrhoea and fatigue. These results should be interpreted
in the context of survival ﬁgures from the Asia-Paciﬁc study
(China, Korea and Taiwan) in which single agent sorafenib was
associated with a median survival of 6.6 months [7], however,
randomised trials are required to demonstrate superiority.Molecular prediction of response to chemotherapy
Tumours are increasingly subjected to molecular proﬁling in
order to select the optimum therapy. In some cases, speciﬁc
mutations or alterations in gene expression are known to predict
drug sensitivity while in others, gene signatures have been asso-
ciated with better outcomes.
MGMT
The sensitivity of tumours to certain alkylating agents has been
linked with the expression levels of the DNA repair enzyme O6-
methylguanine DNA methyltransferase (MGMT). Temozolomide,
streptozocin and decarbazine all induce DNA methylation at the
O6 position of guanine which is not repaired in tumours where
epigenetic silencing of the MGMT gene promoter CpG island pre-
vents MGMT expression. Hence, in glioblastoma, response to
temozolomide has been associated with MGMT expression in
several studies [63,64]. In HCC, methylation of the MGMT pro-
moter has been variably reported and may be related to aetiol-
ogy. In a series from Taiwan, hypermethylation was found in
39% HCC and there appeared to be a relationship between hyper-
methylation and aﬂatoxin B1 DNA adducts [65]. However, other
studies, including those from Japan, have found relatively low
levels of MGMT hypermethylation in comparison to other target
genes [66,67].ERCC1
Another important mechanism of DNA repair is through the
nucleotide excision repair (NER) pathway which is responsible
for the repair of interstrand and intrastrand crosslinks formed
by cisplatin. The excision repair cross-complementation group 1
(ERCC1) is responsible for excising DNA adducts and has an
important role in NER pathway. Increased levels of ERCC1 have
been associated with resistance to platinum-based chemotherapy
in colon, gastric, lung and ovarian cancer. In HCC, ERCC1 expres-
sion has been reported in to be increased in comparison to nor-
mal liver tissues [68,69] and, in vitro, cisplatin sensitivity was
increased using ERCC1 siRNA to inhibit ERCC1 expression. Inter-
estingly, the expression of ERCC1 in hepatocytes has been shown
to increase in response to epidermal growth factor (EGF). While
basal levels could be inhibited by blocking the phosphoinosi-
tide-3-kinase (PI3K) pathway, the response to EGR was inhibited
by blocking the mitogen-activated protein kinase (MAPK) path-
way [70]. This provides a potential rationale for combining EGFR
or MAPK inhibition with platinum chemotherapy in HCC. So
far, the only reported trial combined the anti-EGFR antibody2 vol. 56 j 686–695
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cetuximab with the combination of gemcitabine and oxaliplatin
in a single arm phase II study [36]. The response rate was 20%
with a median PFS of 4.7 months and OS of 9.5 months which
was similar to that reported previously for chemotherapy alone
[32].
AEG1
The recently identiﬁed gene, astrocyte elevated gene-1 (AEG-1),
has also been shown to play a role in chemoresistance. This gene
was ﬁrst identiﬁed as a HIV and TNF-a inducible gene in primary
foetal astrocytes but was shown to promote migration and inva-
sion activating both the Wnt/b-catenin and NF-jB pathway [71].
AEG-1 is expressed in over 90% of HCC samples and overexpres-
sion was found to convert non-tumourigenic HCC cell lines into
aggressive tumours [71]. Recently AEG-1 was also shown to play
an important role in chemoresistance by two separate mecha-
nisms. Firstly, resistance to 5-ﬂuorouracil (5FU) is promoted by
the increased expression of the transcription factor LSF (late
SV40 factor) which upregulates thymidylate synthase (TS), the
target enzyme for 5FU, and also enhances the expression of dihy-
dropyrimidine dehydrogenase (DPD), which catalyses the rate
limiting step in the catabolism of 5FU. In xenografts, the combi-
nation of 5FU and AEG-1 siRNA was superior to either interven-
tion alone in inhibiting growth [72]. Secondly, AEG-1 confers
resistance to doxorubicin by increasing the expression of the
multidrug resistance gene 1 (MDR1) by increasing its translation
and inhibiting its proteosome mediated degradation. Again the
combination of AEG siRNA and doxorubicin was found to be supe-
rior to either agent alone in preclinical models [73].Conclusions
Sorafenib is currently regarded as the standard of care in selected
patients with advanced HCC based on two large randomised pla-
cebo controlled trials. Meanwhile, recent large randomised trials
suggest that cytotoxic chemotherapy also has a modest impact on
survival in this patient group. However, the efﬁcacy of chemo-
therapy is compromised by resistance due to activation of signal-
ling pathways, hypoxia and genetic aberrations. In the last ten
years our understanding of the molecular basis of resistance
has improved, providing an opportunity to explore novel sched-
ules and rational combinations of targeted agents with chemo-
therapy. Targeting mTOR provides a promising means of
abrogating the drug resistance arising from activation of the
PI3K/Akt pathway in p53 wild type tumours while targeting the
G2 checkpoint may overcome resistance in p53mutated tumours.
Sorafenib inhibits signalling through both the Raf/Mek/Erk path-
way and may so reduce the expression of mdr1 and prevent acti-
vation of the hypoxia induced Akt/HIF1/PDGF autocrine loop.
There are already data on the safety and efﬁcacy of sorafenib in
combination with doxorubicin and results of the comparison of
this combination with sorafenib alone are awaited.
Single arm phase II trials are difﬁcult to interpret in this
patient population and randomised phase II trials with time to
progression as a primary endpoint should be performed using
novel combinations compared with standard therapy in order
to establish a justiﬁcation for proceeding to phase III where sur-
vival remains the key endpoint [3]. Patient selection remains of
key importance. In general, only patients with good performanceJournal of Hepatology 201status and well preserved liver function should be treated, in
whom HCC is the life limiting disease and increased toxicity
due to liver impairment is minimised. Molecular pathology may
further help deﬁne subpopulations that should be treated with
targeted agents in combination with chemotherapy.Conﬂict of interest
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